Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

Trial Profile

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms REVERSE-SD
  • Sponsors EIP Pharma
  • Most Recent Events

    • 13 Dec 2018 According to an EIP Pharma media release, the company expects to report top-line data from the trial in the fall of 2019.
    • 13 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to an EIP Pharma media release.
    • 24 Oct 2018 According to a EIP Pharma media release, this trial has reached an important milestone of being more than 50 percent enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top